CLAIMS

1. A recombinant polypeptide of general formula (I):

A-B-C (i)

in which:

A is a cargo molecule;

B is a translocation polypeptide comprising a translocation domain from:

(i) the *Austwickia chelonae* protein of SEQ ID NO: 2; or

(ii) the *Austwickia chelonae LK16-18* protein of GenBank Accession WP_162873017.1; and

C is a targeting moiety.

2. A recombinant polypeptide according to Claim 1, in which the translocation polypeptide comprises the translocation domain from the *Austwickia chelonae* protein, in which the translocation domain has the amino acid sequence of SEQ ID NO: 3.

3. A recombinant polypeptide according to Claim 1, in which the translocation polypeptide comprises the translocation domain from the *Austwickia chelonae LK16-18* protein of GenBank Accession WP_162873017.1, in which the translocation domain has the amino acid sequence of SEQ ID NO: 17.

4. A recombinant polypeptide according to any Claim 1, 2 or 3, in which A and B are separated by an amino acid linker,

preferably in which the amino acid linker comprises $(G_4S)_2$,

more preferably in which the amino acid linker is cleavable,

more preferably in which the amino acid linker comprises a protease recognition site,

more preferably in which the protease recognition site is bracketed by cysteine residues,

more preferably in which the protease recognition site is a furin protease recognition site,

more preferably in which the amino acid linker comprises SEQ ID NO: 32, which comprises the furin protease recognition site,

more preferably in which the $(G_4S)_2$ is positioned N-terminally with respect to the SEQ ID NO: 32.

5. A recombinant polypeptide according to any preceding claim, in which B and C are separated by an amino acid linker,

preferably in which the amino acid linker comprises SEQ ID NO: 33,

more preferably in which the $(G_4S)_2$ is positioned N-terminally with respect to the SEQ ID NO: 33.

6. A recombinant polypeptide according to any preceding claim, in which the targeting moiety comprises a targeting polypeptide or aptamer,

preferably in which the targeting polypeptide comprises an antibody, a binding fragment of an antibody, an affibody, a peptide, an affitin, a DARPin, or a receptor ligand,

more preferably in which the receptor ligand for αvβ6 integrin comprises the amino acid sequence of SEQ ID NO: 20.

7. A recombinant polypeptide according to Claim 6, in which the targeting moiety comprises at least two targeting polypeptides, at least two aptamers, or a combination of a targeting polypeptide and an aptamer.

8. A recombinant polypeptide according to any preceding claim, in which the targeting moiety binds to a cell surface protein,

preferably in which the cell surface protein is expressed in a disease cell,

more preferably in which the disease cell is a cancer cell.

9. A recombinant polypeptide according to any preceding claim, in which the cargo molecule comprises a therapeutic polypeptide,

preferably in which the therapeutic polypeptide comprises a cytotoxic polypeptide,

more preferably a polypeptide toxin or a functional fragment thereof.

10. A recombinant polypeptide according to Claim 9, in which the cytotoxic polypeptide comprises a catalytic domain from a Chelona Toxin,

preferably in which the catalytic domain is from:

the Chelona Toxin set forth in SEQ ID NO: 2 (CT1);

the Chelona Toxin set forth in SEQ ID NO: 21 (CT2); or

the Chelona Toxin set forth in SEQ ID NO: 35 (CT3).

11. A recombinant polypeptide according to Claim 10, in which the catalytic domain from the Chelona Toxin set forth in SEQ ID NO: 2 (CT1) has the amino acid sequence according to amino acid positions 1 to 186 of SEQ ID NO: 2.

12. A recombinant polypeptide according to Claim 10, in which the catalytic domain from the Chelona Toxin set forth in SEQ ID NO: 21 (CT2) has the amino acid sequence according to amino acid positions 1 to 186 of SEQ ID NO: 21.

13. A recombinant polypeptide according to Claim 10, in which the catalytic domain from the Chelona Toxin set forth in SEQ ID NO: 35 (CT3) has the amino acid sequence according to amino acid positions 1 to 191 of SEQ ID NO: 35.

14. A pharmaceutical composition comprising a recombinant polypeptide according to any preceding claim, together with a pharmaceutically acceptable excipient, diluent, or carrier.

15. A recombinant polypeptide according to any of Claims 1 to 13 for use in the treatment of cancer in a subject.